Incorrect Financial Disclosure | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Sign In
January 2014

Incorrect Financial Disclosure

JAMA Dermatol. 2014;150(1):103. doi:10.1001/jamadermatol.2013.9598

In the Original Investigation titled “Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011” published online August 14, 2013, and also in the October print issue of JAMADermatology (2013;149[10]:1180-1185. doi:10.1001/jamadermatol.2013.5264), incorrect information appeared in the Conflict of Interest Disclosures section of the Article Information on page 1185. That section should have appeared as follows: “Dr Armstrong has received research grants or consultant honoraria from Abbott Laboratories, Amgen, Inc, and Janssen Biotech. Dr Lebwohl has been a consultant and/or investigator for Abbott Laboratories, Amgen, Inc, Anacor Pharmaceuticals, Inc, BioLine RX, Ltd, Celgene Corporation, Columbia Laboratories, Inc, Coronado Biosciences, Dermipsor, Ltd, Eli Lilly & Co, Galderma, GlaxoSmithKline-Stiefel, Janssen Ortho Biotech, LEO Pharmaceuticals, Maruho Co, Ltd, Meda Pharmaceuticals, Novartis, Pfizer, Ranbaxy Laboratories, Ltd, Thesan Pharmaceuticals, and Valeant Pharmaceuticals. The other authors reported no disclosures.” This article was corrected online.